ArticleBMC cancer2025
Spatial transcriptomics of retinoblastoma: a visual window on intra-patient heterogeneity.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Retinoblastoma and Its Tumor Microenvironment.Current oncology (Toronto, Ont.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRetinoblastoma is the most common intraocular malignant tumor in childhood. Although current treatments offer a high survival rate, treatment toxicity, tumor relapse, and treatment resistance require a deeper understanding of the disease mechanisms to develop adapted therapies. Microscopically, this tumor is characterized by different states of differentiation and proliferation, ranging from poorly differentiated to well-differentiated retinoblastoma. Retinocytoma, on the other hand, is a benign non-proliferative tumor. Recent next-generation multi-omics analyses classified retinoblastoma tumors in subtypes 1 or 2, subtype 2 presenting a later age of onset, more genetic alterations, and higher metastatic potential. In parallel, several single-cell transcriptomics studies demonstrated intratumoral heterogeneity. However, mapping the different cell populations directly on the tumor and comparing histological features and molecular subtypes remains an unmet need.
methodsSpatial transcriptomics was used to characterize a primary enucleated case with two histologically distinct areas. The whole transcriptomic profile of sixteen regions of interest, covering the two differentiation patterns of the tumor and the non-tumoral retina, was analyzed.
resultsThe clustering of the regions of interest based on whole transcriptome data correlated with the histological description: cluster 1 (6 regions of interest) corresponded to highly differentiated areas and cluster 2 (6 regions of interest) to poorly differentiated areas. They showed enrichment for phototransduction and proliferation respectively, confirmed by immunohistochemistry for markers of these pathways. The publicly available molecular signatures of the two retinoblastoma subtypes categorized our regions of interest into two groups, which correlated perfectly with histological observation and transcriptomic profiles. Further analysis of the expression of specific senescence markers in the well-differentiated area did not support the diagnosis of retinocytoma as it did not confirm the expected up-regulation seen in this tumor type.
conclusionsThis study demonstrates a strong correlation between histological observation and molecular profiling, representing the first mapping of retinoblastoma composed of adjacent molecular subtypes 1 and 2. It also highlights the diagnostic ambiguity between retinocytoma and well-differentiated non-proliferative subtype 1 retinoblastoma and emphasizes the need for specific biomarkers to differentiate these two tumor types.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.